Timing of Stent Thrombosis After 1-Month Discontinuation of Dual Antiplatelet Therapy

TY - JOUR

T1 - Timing of Stent Thrombosis After 1-Month Discontinuation of Dual Antiplatelet Therapy

AU - Thangam, Manoj

AU - Nazif, Tamim M.

AU - Parke, Maria

AU - Kandzari, David E.

AU - Windecker, Stephan

AU - Latib, Azeem

AU - Kedhi, Elvin

AU - Mehran, Roxana

AU - Stone, Gregg W.

AU - Kirtane, Ajay J.

N1 - Funding Information: Ms Parke is an employee of Medtronic. Dr Kandzari has received institutional research/grant support from Abbott Vascular, Biotronik, Boston Scientific, Cardiovascular Systems, Orbus Neich, Medtronic, and Ablative Solutions; and has received personal consulting honoraria from Cardiovascular Systems, Magenta Medical, and Medtronic. Dr Windecker serves as unpaid advisory board member and/or unpaid member of the steering/executive committee for trials funded by Abbott, Abiomed, Amgen, AstraZeneca, Bristol Myers Squibb, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis, but has not received personal payments by pharmaceutical companies or device manufacturers; and is a member of the steering/executive committee for several investigator-initiated trials that receive funding by industry without impact on personal remuneration. Dr Latib has received consulting fees from Medtronic, Abbott Vascular, and Boston Scientific. Dr Kedhi has received speaker honoraria and institutional grants from Medtronic and Abbott Vascular. Dr Mehran has reeived institutional research grants from Abbott Laboratories, Abiomed, Applied Therapeutics, AstraZeneca, Bayer, Beth Israel Deaconess, Bristol Myers Squibb, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Medtronic, Novartis Pharmaceuticals, and OrbusNeich; has received consultant fees from Abbott Laboratories, Boston Scientific, CardiaWave, Chiesi, Cine-Med Research, Janssen Scientific Affairs, Medscape/WebMD, Medtelligence (Janssen Scientific Affairs), Roivant Sciences, Sanofi, and Siemens Medical Solutions; has received consultant fees paid to the institution from Abbott Laboratories and Bristol Myers Squibb; has received advisory board funding paid to the institution from Spectranetics/Philips/Volcano Corp; spouse is a consultant for Abiomed, The Medicines Company, and Merck; has equity <1% with Claret Medical, Elixir Medical, Applied Therapeutics, and STEL; has received data and safety monitoring board membership fees paid to the institution from Watermark Research Partners; has been a consultant for (no fees) Idorsia Pharmaceuticals and Regeneron Pharmaceuticals; and is Associate Editor for the American College of Cardiology and American Medical Association. Dr Stone has received speaker honoraria from Cook, Infraredx, Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Vectorious, Miracor, Neovasc, Abiomed, Ancora, Elucid Bio, Occlutech, CorFlow, Apollo Therapeutics, Impulse Dynamics, Reva, Vascular Dynamics, Shockwave, V-Wave, Cardiomech, and Gore; and has equity/options with Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, and MedFocus family of funds. Dr Kirtane has received institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Amgen, CSI, Philips, ReCor Medical, Neurotronic, Biotronik, Chiesi, Bolt Medical, Magenta Medical, Canon, and SoniVie, including fees paid to Columbia University and/or Cardiovascular Research Foundation for consulting and/or speaking engagements; has received consulting fees from IMDS; and has received travel expenses/meals paid from Medtronic, Boston Scientific, Abbott Vascular, CSI, Siemens, Philips, ReCor Medical, Chiesi, OpSens, Zoll, and Regeneron. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: Ms Parke is an employee of Medtronic. Dr Kandzari has received institutional research/grant support from Abbott Vascular, Biotronik, Boston Scientific, Cardiovascular Systems, Orbus Neich, Medtronic, and Ablative Solutions; and has received personal consulting honoraria from Cardiovascular Systems, Magenta Medical, and Medtronic. Dr Windecker serves as unpaid advisory board member and/or unpaid member of the steering/executive committee for trials funded by Abbott, Abiomed, Amgen, AstraZeneca, Bristol Myers Squibb, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis, but has not received personal payments by pharmaceutical companies or device manufacturers; and is a member of the steering/executive committee for several investigator-initiated trials that receive funding by industry without impact on personal remuneration. Dr Latib has received consulting fees from Medtronic, Abbott Vascular, and Boston Scientific. Dr Kedhi has received speaker honoraria and institutional grants from Medtronic and Abbott Vascular. Dr Mehran has reeived institutional research grants from Abbott Laboratories, Abiomed, Applied Therapeutics, AstraZeneca, Bayer, Beth Israel Deaconess, Bristol Myers Squibb, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Medtronic, Novartis Pharmaceuticals, and OrbusNeich; has received consultant fees from Abbott Laboratories, Boston Scientific, CardiaWave, Chiesi, Cine-Med Research, Janssen Scientific Affairs, Medscape/WebMD, Medtelligence (Janssen Scientific Affairs), Roivant Sciences, Sanofi, and Siemens Medical Solutions; has received consultant fees paid to the institution from Abbott Laboratories and Bristol Myers Squibb; has received advisory board funding paid to the institution from Spectranetics/Philips/Volcano Corp; spouse is a consultant for Abiomed, The Medicines Company, and Merck; has equity <1% with Claret Medical, Elixir Medical, Applied Therapeutics, and STEL; has received data and safety monitoring board membership fees paid to the institution from Watermark Research Partners; has been a consultant for (no fees) Idorsia Pharmaceuticals and Regeneron Pharmaceuticals; and is Associate Editor for the American College of Cardiology and American Medical Association. Dr Stone has received speaker honoraria from Cook, Infraredx, Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Vectorious, Miracor, Neovasc, Abiomed, Ancora, Elucid Bio, Occlutech, CorFlow, Apollo Therapeutics, Impulse Dynamics, Reva, Vascular Dynamics, Shockwave, V-Wave, Cardiomech, and Gore; and has equity/options with Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, and MedFocus family of funds. Dr Kirtane has received institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Amgen, CSI, Philips, ReCor Medical, Neurotronic, Biotronik, Chiesi, Bolt Medical, Magenta Medical, Canon, and SoniVie, including fees paid to Columbia University and/or Cardiovascular Research Foundation for consulting and/or speaking engagements; has received consulting fees from IMDS; and has received travel expenses/meals paid from Medtronic, Boston Scientific, Abbott Vascular, CSI, Siemens, Philips, ReCor Medical, Chiesi, OpSens, Zoll, and Regeneron. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2022/5/17

Y1 - 2022/5/17

UR - http://www.scopus.com/inward/record.url?scp=85129427207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129427207&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2022.03.342

DO - 10.1016/j.jacc.2022.03.342

M3 - Letter

C2 - 35550693

AN - SCOPUS:85129427207

SN - 0735-1097

VL - 79

SP - 1963

EP - 1965

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 19

ER -